Yunsong Qian
Overview
Explore the profile of Yunsong Qian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
53
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zou P, Bi Y, Tong Z, Wu T, Li Q, Wang K, et al.
Trials
. 2024 Nov;
25(1):799.
PMID: 39605077
Background: Hepatic encephalopathy (HE) represents a critical complications of end-stage liver disease, serving as an independent predictor of mortality among patients with cirrhosis. Despite effective treatment with rifaximin, some patients...
2.
Guo L, Hao X, Chen L, Qian Y, Wang C, Liu X, et al.
EClinicalMedicine
. 2024 Jul;
74:102718.
PMID: 39070173
Background: The diagnosis of hepatocellular carcinoma (HCC) often experiences latency, ultimately leading to unfavorable patient outcomes due to delayed therapeutic interventions. Our study is designed to develop and validate a...
3.
Ou H, Qian Y, Ma L
Aging (Albany NY)
. 2023 Jul;
15(13):6100-6116.
PMID: 37432067
Long noncoding RNA MCF2L-AS1 functions in the development of cancers like lung cancer, ovarian cancer, and colorectal cancer. Notwithstanding, its function in hepatocellular carcinoma (HCC) stays obscure. Our research probes...
4.
Fan R, Chen L, Zhao S, Yang H, Li Z, Qian Y, et al.
J Hepatol
. 2023 Jun;
79(4):933-944.
PMID: 37302583
Background & Aims: Current hepatocellular carcinoma (HCC) risk scores do not reflect changes in HCC risk resulting from liver disease progression/regression over time. We aimed to develop and validate two...
5.
Huang Y, Chen L, Huang R, Zhu C, Shang J, Qian Y, et al.
Ther Adv Chronic Dis
. 2022 Jun;
13:20406223221102791.
PMID: 35757781
Background: Both tenofovir disoproxil fumarate (TDF) and entecavir (ETV) are known to reduce the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). This study aimed to...
6.
Qian Y, Li L, Ma L, Ji R, Ying S, Zhou J, et al.
J Clin Lab Anal
. 2022 Feb;
36(4):e24296.
PMID: 35218083
Background: Previous studies have developed some blood-based biomarker algorithms such as the Doylestown algorithm and aMAP score to improve the detection of Hepatocellular carcinoma (HCC). However, no one has studied...
7.
Lei X, Zhang J, Xu Q, Li J, Qian Y, Zhang J, et al.
J Int Med Res
. 2021 Aug;
49(8):3000605211039810.
PMID: 34433332
In China, polyene phosphatidylcholine (PPC) is widely used to treat alanine aminotransferase (ALT) elevation associated with various liver diseases. Here, we assessed the efficacy and safety of PPC in treating...
8.
Wang S, Hu M, Qian Y, Jiang Z, Shen L, Fu L, et al.
Biomed Pharmacother
. 2020 Aug;
131:110680.
PMID: 32861071
Chitinase 3-like protein 1(CHI3L1) participates in physiological and pathophysiological process, such as cell survival, cell proliferation, tissue remodeling, angiogenesis, etc. Some studies demonstrated that CHI3L1 is liver-enriched and has better...
9.
Jiang Z, Wang S, Jin J, Ying S, Chen Z, Zhu D, et al.
J Clin Lab Anal
. 2020 Jan;
34(5):e23200.
PMID: 31916309
Aim: In the present study, we purposed to determine serum chitinase 3-like 1 (CHI3L1) expression characteristics in chronic liver diseases monoinfected with hepatitis B virus and analyze its diagnostic value...